COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,629 Articles (22,913 medRxiv, 8,716 bioRxiv)

Most recent first Previous |  Page 1082: Articles 10811-10820  | Next

Rapid longitudinal SARS-CoV-2 intra-host emergence of novel haplotypes regardless of immune deficiencies
Manuto, L., Grazioli, M., Spitaleri, A., Fontana, P., Bianco, L., Bertolotti, L., Bado, M., Mazzotti, G., Bianca, F., Onelia, F., Lorenzin, G., Simeoni, F., Lazarevic, D., Franchin, E., Del Vecchio, C., Dorigatti, I., Tonon, G., Cirillo, d., Lavezzo, E., Crisanti, A., Toppo, S.
10.1101/2021.12.22.473949 — Posted: 2021-12-23
SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-weeks interval between doses
Chatterjee, D., Tauzin, A., Marchitto, L., Gong, S. Y., Boutin, M., Bourassa, C., Beaudoin-Bussieres, G., Bo, Y., Ding, S., Laumaea, A., Vezina, D., Perreault, J., Gokool, L., Morrisseau, C., Arlotto, P., Fournier, E., Guilbault, A., Delisle, B., Levade, I., Goyette, G., Gendron-Lepage, G., Medjahed, H., De Serres, G., Tremblay, C., Martel-Laferriere, V., Kaufmann, D. E., Bazin, R., Prevost, J., Moreira, S., Richard, J., Cote, M., Finzi, A.
10.1101/2021.12.21.473679 — Posted: 2021-12-23
SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster
Lusvarghi, S., Pollett, S. D., Neerukonda, S. N., WANG, W., Wang, R., Vassell, R., Epsi, N. J., Fries, A. C., Agan, B. K., Lindholm, D. A., Lalani, T., Mody, R., Ewers, E. C., Lalani, T., Ganesan, A., Goguet, E., Hollis-Perry, M., Coggins, S. A., Simons, M. P., Katzelnick, L. C., Wang, G., Broder, C. C., Tribble, D. R., Bentley, L. M., Eakin, A. E., Erlandson, K. J., Laing, E. D., Burgess, T. H., Mitre, E., Weiss, C. D.
10.1101/2021.12.22.473880 — Posted: 2021-12-23
Engineered ACE2 counteracts vaccine-evading SARS-CoV-2 Omicron variant
Ikemura, N., Taminishi, S., Inaba, T., Arimori, T., Motooka, D., Katoh, K., Kirita, Y., Kirita, Y., Li, S., Itoh, Y., Ozaki, Y., Nakamura, S., Matoba, S., Standley, D. M., Okamoto, T., Takagi, J., Hoshino, A.
10.1101/2021.12.22.473804 — Posted: 2021-12-23
Interferon-induced transmembrane protein 3 (IFITM3) limits lethality of SARS-CoV-2 in mice
Zani, A., Kenney, A., Kawahara, J., Eddy, A. C., Wang, X.-L., KC, M., Lu, M., Hemann, E. A., Li, J., Peeples, M. E., Hall-Stoodley, L., Forero, A., Cai, C., Ma, J., Yount, J. S.
10.1101/2021.12.22.473914 — Posted: 2021-12-23
Broad and Long-lasting Immune Response against SARS-CoV-2 Omicron and Other Variants by PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine (YS-SC2-010)
Liu, Y., Zhang, N., Wang, B., Zhang, Y.
10.1101/2021.12.22.473615 — Posted: 2021-12-23
Waning immune responses against SARS-CoV-2 among vaccinees in Hong Kong
Peng, Q., Zhou, R., Wang, Y., Zhao, M., Liu, N., Li, S., Huang, H., Yang, D., Au, K.-K., Wang, H., Man, K., Yuen, K.-Y., Chen, Z.
10.1101/2021.12.22.473934 — Posted: 2021-12-23
Accelerating manufacturing to start large-scale supply of a new adenovirus-vectored vaccine within 100 days
Joe, C. C., Segireddy, R. R., Oliveira, C., Berg, A., Li, Y., Doultsinos, D., Chopra, N., Scholze, S., Ahmad, A., Nestola, P., Niemann, J., Douglas, A.
10.1101/2021.12.22.473478 — Posted: 2021-12-23
Surveillance and correlation of SARS-CoV-2 viral RNA, antigen, virus isolation, and self-reported symptoms in a longitudinal study with daily sampling
Bonenfant, G., Deyoe, J., Wong, T., Grijalva, C. G., Talbot, H. K., Halasa, N., Chappell, J., Cui, D., Hassell, N., Thornburg, N. J., Rolfes, M. A., Wentworth, D., Zhou, B.
10.1101/2021.12.23.21268319 — Posted: 2021-12-23
Dynamics of immune recall following SARS-CoV-2 vaccination or breakthrough infection
Koutsakos, M., Lee, W. S., Reynaldi, A., Tan, H.-X., Gare, G., Kinsella, P., Liew, K. C., Williamson, D. A., Kent, H. E., Stadler, E., Cromer, D., Khoury, D. S., Wheatley, A. K., Juno, J. A., Davenport, M. P., Kent, S. J.
10.1101/2021.12.23.21268285 — Posted: 2021-12-23

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).